NCT01142193

Study to Evaluate the Safety and Effectiveness of USL255 in Patients With Refractory Partial-onset Seizures

A Randomized, Multicenter, Double-blind, Placebo-controlled, Parallel-group Phase 3 Study to Evaluate the Efficacy and Safety of USL255 as Adjunctive Therapy in Patients With Refractory Partial-Onset Seizures

• Status: Completed
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 249 (actual)
• Sponsor: Upsher-Smith Laboratories · Industry
• Sex: All
• Age: 18 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to examine the safety and effectiveness of USL255 as adjunctive therapy in patients with refractory partial onset-seizures.

Conditions

• Epilepsy

Interventions

Type	Name	Description
DRUG	USL255
DRUG	Placebo

Timeline

• Start date: 2010-05-01
• Primary completion: 2012-12-01
• Completion: 2013-01-01
• First posted: 2010-06-11
• Last updated: 2014-05-22
• Results posted: 2014-05-07

Locations

69 sites across 16 countries: United States, Argentina, Australia, Belgium, Canada, Chile, Germany, Greece, Hungary, India, Israel, New Zealand, Poland, Russia, South Africa, Spain